Matthew W. Onaitis
Director of Finance/CFO chez MAINSTAY MEDICAL INTERNATIONAL
Profil
Matthew W.
Onaitis is currently the Director at Snp Bio, Inc. and Stratify Genomics, Inc. He is also the Chief Financial Officer & Secretary at Mainstay Medical International Ltd.
and the Chief Financial Officer at Mainstay Medical Holdings Plc.
Previously, Mr. Onaitis held positions as the Director-Legal Affairs at Elan Corp.
Plc from 2004 to 2005, Associate General Counsel at Biogen, Inc. in 2006, Secretary, Senior Vice President & General Counsel at Somaxon Pharmaceuticals, Inc. from 2006 to 2013, Secretary & General Counsel at Trius Therapeutics, Inc. in 2013, Secretary & General Counsel at Ignyta, Inc. from 2014 to 2016, and CFO, Secretary, CAO & General Counsel at Cidara Therapeutics, Inc. in 2018.
Mr. Onaitis obtained his undergraduate degree from Carnegie Mellon University in 1993 and his graduate degree from Stanford Law School in 1998.
Postes actifs de Matthew W. Onaitis
| Sociétés | Poste | Début |
|---|---|---|
| MAINSTAY MEDICAL INTERNATIONAL | Director of Finance/CFO | 20/08/2018 |
| Snp Bio, Inc. | Director/Board Member | - |
Stratify Genomics, Inc.
 Stratify Genomics, Inc. Medical/Nursing ServicesHealth Services Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA. | Director/Board Member | - |
Mainstay Medical Holdings Plc
 Mainstay Medical Holdings Plc Financial ConglomeratesFinance Mainstay Medical Holdings Plc is a medical device company, which focuses on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain. The company was founded in 2020 and is headquartered in Dublin, Ireland. | Director of Finance/CFO | - |
Anciens postes connus de Matthew W. Onaitis
| Sociétés | Poste | Fin |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Director of Finance/CFO | 17/08/2018 |
| IGNYTA INC | General Counsel | 01/06/2016 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | General Counsel | 01/12/2013 |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | General Counsel | 01/03/2013 |
| BIOGEN INC. | Corporate Officer/Principal | 01/05/2006 |
Formation de Matthew W. Onaitis
| Carnegie Mellon University | Undergraduate Degree |
| Stanford Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Health Technology |
Mainstay Medical International Ltd.
 Mainstay Medical International Ltd. Medical SpecialtiesHealth Technology Mainstay Medical International Ltd. is a medical device company, which is engages in the development of neurostimulation system. It focuses on the study of ReActiv8, a medical device designed to treat people with chronic low back pain. The company was founded by Danny Sachs in 2008 and is headquartered in San Diego, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| Snp Bio, Inc. | |
Stratify Genomics, Inc.
Stratify Genomics, Inc. Medical/Nursing ServicesHealth Services Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA. | Health Services |
Mainstay Medical Holdings Plc
Mainstay Medical Holdings Plc Financial ConglomeratesFinance Mainstay Medical Holdings Plc is a medical device company, which focuses on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain. The company was founded in 2020 and is headquartered in Dublin, Ireland. | Finance |
